Operator
Good morning. My name is Kaylee, and I'll be your conference operator today. At this time, I would like to welcome everyone to Provention Bio call. [Operator Instructions] Please be advised that this call is being recorded at the company's request.
I would now like to hand the conference over to Mr. Robert Doody, Vice President of Investor Relations for Provention Bio.
Robert A. Doody --
Investor Relation
Thank you operator, and thank you all for joining us on Provention Bio's first quarter 2021 financial results conference call. Joining today's call from Provention Bio team is Ashleigh Palmer, Chief Executive Officer and Co-Founder; Andrew Drechsler, Chief Financial Officer; and the other members of the Provention Bio leadership team. Before we begin, let me remind you that the various remarks we will make today constitute forward-looking statements. These include statements about our future expectations, clinical results, regulatory and other developments and timelines related to our product candidates. Including for the teplizumab BLA. Such as our plans to work with the FDA to resolve their PK comparability concerns and expectations for the upcoming advisory committee meeting. The potential safety, efficacy and commercial success of teplizumab and our other product candidates.